Cashu Logo
HomeWatchlistNewsSignalsPicks
DJI
+0.37%
SPX
+0.49%
IXIC
+0.71%
FTSE
-0.12%
N225
0.00%
AXJO
0.00%
Cashu Logo
Log In
HomeWatchlistNewsSignalsPicks
Stocks
0.00 (0.00%)
0.000
USD
At close at --,----
Cashu Logo Alt
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.

Company

  • About Us
  • Careers
  • Blog
  • News

Help & Support

  • Help Center
  • Contact Us
  • Pro Support

Legal

  • Privacy Policy
  • Terms of Use
InstagramYouTube

© 2024 Cashu PTY LTD.

Join our newsletter to keep up to date with us!

Overview

Loading chart...

Key Stats

Market Cap
2.41B
Dividend Yield
0.00%
P/E Ratio
-6.56
EPS
-0.59
Revenue
14.74M
Avg. Volume
16.04M

About

What does IBRX do?
ImmunityBio is a San Diego-based clinical stage immunotherapy company with 628 employees, focusing on therapies for urologic cancers and infectious diseases. Its lead product candidate, Anktiva, is an IL-15 superagonist fusion protein.
Sector
💻 Health Care
IPO
CEO
Employees
680
Headquarters
California, USA
Stocks
Health Care
ibrx
ImmunityBio
NASDAQ: IBRX
-0.12 (-4.21%)
2.73
USD
At close at Sep 19, 20:39 UTC
Summary
News
Signals
Benchmarks
Financials

Recently from Cashu

publisher logo
Cashu

ImmunityBio and Oncolytics Biotech Propel Cancer Treatment Forward with GOBLET Study Advances

3 days ago
publisher logo
Cashu

ImmunityBio: Oncolytics Biotech's GOBLET Study Shows Promise in Cancer Treatment Advancements

5 days ago
publisher logo
Cashu

ImmunityBio Attracts Retail Investor Interest Amid Meme Stock Surge

8 days ago